Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA(1c) and Insulin Use: An Analysis From the FIDELIO-DKD Study

OBJECTIVE: Finerenone significantly improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial. We explored whether baseline HbA(1c) level and insulin trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossing, Peter, Burgess, Ellen, Agarwal, Rajiv, Anker, Stefan D., Filippatos, Gerasimos, Pitt, Bertram, Ruilope, Luis M., Gillard, Pieter, MacIsaac, Richard J., Wainstein, Julio, Joseph, Amer, Brinker, Meike, Roessig, Lothar, Scott, Charlie, Bakris, George L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2022
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271031/
https://www.ncbi.nlm.nih.gov/pubmed/35061867
http://dx.doi.org/10.2337/dc21-1944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271031/
https://www.ncbi.nlm.nih.gov/pubmed/35061867
http://dx.doi.org/10.2337/dc21-1944

Ejemplares similares